Phase 3 N=400 Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate (AERR) — 0.42; 1.63 Events per year — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=894 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
Asthma
Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.97; 0.77; 0.93 events/year — p=0.800
Phase 3 N=877 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
Asthma
Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.73; 0.76; 1.06 Events/year — p=0.059
Phase 3 N=1,061 Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma — 0.93; 2.10 events per year — p=<0.001
Phase 3 N=41 Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
Asthma
Primary: Change From Baseline in the Expression of FcεRI Receptors of Blood Basophils — -84.4; 27.7 Percent change in MFI
Phase 4 N=406 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Asthma
Primary: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness (GETE) — 190; 29; 187; 28 participants
Phase 2 N=502 A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
Asthma
Primary: Reduction in Rate of Asthma Exacerbations — 0.74; 0.47; 0.58; 0.42 Number of asthma exacerbations per year — p=0.0049
N/A N=39 Inflammation and Corticosteroid Responsiveness in Severe Asthma
Asthma
Primary: Lung Function FEV1 — 84.9; 59.9 % of predicted — p=0.001
Phase 3 N=576 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
Asthma
Primary: Number of Clinically Significant Exacerbations of Asthma Per Year — 1.74; 0.93; 0.83 Number of exacerbations per year — p=<0.001
Phase 2 N=15 A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma
Severe, Refractory Asthma · Airway Inflammation · Airflow Obstruction
Primary: 16 Weeks - Juniper Asthma Quality of Life Questionnaire (AQLQ) Score — 4.7; 4.6 units on a scale
Phase 3 N=551 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
Asthma
Primary: Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 24 — -7.9; -15.6 Scores on a scale — p=<0.001
N/A N=34 Research in Severe Asthma (RISA) Trial
Asthma
Primary: Respiratory Adverse Events Per Subject — 9.1; 3.4; 2.6; 2.2 Respiratory Adverse Events/Subject
Phase 3 N=300 A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
Asthma
Primary: Rate of Clinically Significant Exacerbations of Asthma — 0.45; 1.31 Exacerbations per year — p=<0.001
Phase 2 N=118 Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
Asthma
Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) — 0.043; 0.016 Liters — p=0.7374
Phase 2 N=550 Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
Asthma
Primary: Annualized Asthma Exacerbation Rate (AER) Through Week 52 — 0.72; 0.27; 0.20; 0.23 events per person-year — p=<0.001
Phase 3 N=135 Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
Asthma
Primary: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control — 7…
Phase 3 N=850 A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
Asthma
Primary: Rate of Asthma Exacerbations Over the 48 Week Treatment Period — 0.88; 0.66 exacerbation/patient-week
Phase 3 N=616 Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
Persistent Allergic Asthma
Primary: Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period — 27.03; 18.18 L/min
Phase 3 N=1,205 Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL — 0.73; 0.65; 1.33 events/year — p=<0.001
Phase 4 N=221 Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data
Asthma
Primary: Percentage of Well Controlled Participants as Per Gaining Optimal Asthma Control (GOAL) Criteria After 12 Week Compared to Percentage of Participants With Asthma Control…
Phase 3 N=1,437 TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Asthma
Primary: 1_Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Week 26 — 0.229; 0.157; 0.274 Liter — p=0.003
Phase 2 N=64 Roflumilast Plus Montelukast in Adults With Severe Asthma
Asthma
Primary: Change From Baseline in Pre-Dose (Trough) Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) — 0.18; 0.08 liters — p=0.013
Phase 2 N=640 A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.
Asthma
Primary: Rate of Severe Asthma Exacerbations During 6 Months — 0.31; 0.31; 0.26; 0.20 Exacerbations per 6 month — p=0.119
Phase 2 N=21 Personalized Treatment Algorithms for Difficult-to-treat Asthma
Asthma in Children
Primary: Change in Composite Asthma Severity Index (CASI) — 5; 5; 5 score on a scale — p=0.52
Phase 4 N=271 Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
Persistent Allergic Asthma
Primary: Change From Baseline in Asthma Control Test (ACT) After 24 Weeks of Treatment — 5.2; 4.7 Score on a scale
Phase 3 N=220 Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
Asthma
Primary: Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control — 75.00; 75.00; 25.00 Percent — p=<0.001
Phase 2 N=198 Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
Asthma
Primary: Change From Baseline in Asthma Control Questionnaire (ACQ-7) Over 12 Weeks — -0.1; -0.2; -0.1; -0.3 Scores on Scale — p=0.1955
Phase 3 N=695 Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
Asthma
Primary: Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL — 0.49; 1.88 events/patient-year…
Phase 4 N=478 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
Asthma
Primary: Occurrence of One or More Asthma Exacerbations (All Treatment Steps [Steps 2-5]) — 11.3; 21.0 Percent of adjusted prevalence — p=0.03
Phase 2 N=616 Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
Asthma
Primary: Number of Clinically Significant Exacerbations of Asthma Per Year — 2.40; 1.24; 1.46; 1.15 Exacerbations per year — p=<0.001